Discovery of Dipyridamole Analogues with Enhanced Metabolic Stability for the Treatment of Idiopathic Pulmonary Fibrosis

Dipyridamole, apart from its well-known antiplatelet and phosphodiesterase inhibitory activities, is a promising old drug for the treatment of pulmonary fibrosis. However, dipyridamole shows poor pharmacokinetic properties with a half-life (T(1/2)) of 7 min in rat liver microsomes (RLM). To improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Meng-Xing, Chen, Yan-Quan, Liu, Run-Duo, Huang, Yue, Zhang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182104/
https://www.ncbi.nlm.nih.gov/pubmed/35684390
http://dx.doi.org/10.3390/molecules27113452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182104/
https://www.ncbi.nlm.nih.gov/pubmed/35684390
http://dx.doi.org/10.3390/molecules27113452

Ejemplares similares